Auriga

Auriga Partners is a Paris-based venture capital firm established in 1998. The firm specializes in early-stage investments across various sectors, including information technology, life sciences, and cybersecurity. Auriga Partners has a strong focus on supporting high-potential ventures in Europe, North America, and Israel. Notable investments by Auriga Partners include Vade Secure, Nexthink, and Exeliom Biosciences. Vade Secure, a leader in predictive email defense, and Nexthink, a prominent analytics software provider, highlight Auriga’s commitment to backing innovative tech companies. Exeliom Biosciences, a biotech firm focused on the development of microbiome therapeutics, demonstrates their investment in life sciences. Auriga Partners has a robust portfolio with over 171 investments and 77 exits, reflecting their extensive experience and successful track record in venture capital. Their approach involves not only providing capital but also leveraging their expertise and network to support the growth and development of their portfolio companies. The team at Auriga Partners includes seasoned professionals like Philippe Granger, Mathieu Chatain, and Nabil Gharios, who bring significant industry knowledge and investment experience.